Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cavilon Durable Barrier · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cavilon (TM) Durable Barrier Cream | DRUG | Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation. |
| Sorbolene | DRUG | Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation |
| Radiotherapy | RADIATION | Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol |
Inclusion Criteria: * Ages 18 or more years * Post total mastectomy * Planned dose at least 45 Gy in 25 fractions * ECOG 0-2 * Able to attend weekly during treatment for review and photo and for up to 6 weeks after radiotherapy * Patients capable of childbearing using adequate contraception * Writt...
Top 20 of 92 competitors
Cavilon Durable Barrier is a small molecule being studied for use in breast cancer patients. It is a barrier cream that was evaluated in a Phase 3 clinical trial for its effects compared to a glycerine cream. The investigational product is intended for topical application, though the specific clinical use in breast cancer is not detailed.
Cavilon Durable Barrier is developed by 3M Company, which trades under the ticker MMM. The company conducted a Phase 3 clinical trial of the product in breast cancer patients. 3M is the sole developer of this investigational barrier cream.
Cavilon Durable Barrier is in Phase 3 clinical development. The Phase 3 trial, NCT00193908, has been completed. The product is investigational and has not been approved by regulatory authorities. It remains in clinical development for its potential use in breast cancer.
Cavilon Durable Barrier has one completed Phase 3 clinical trial, NCT00193908, titled "Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine (\"Sorbolene\") Cream." The trial enrolled 333 participants with breast cancer in Australia and was randomized, double-blind, and controlled.
Cavilon Durable Barrier does not have a specified molecular target or target class. It is a barrier cream, and its mechanism of action is not described in the available data. The product is being studied for its effects in breast cancer patients, but no specific biological target has been identified.
Cavilon Durable Barrier is not the same as Sorbolene cream. In the Phase 3 clinical trial NCT00193908, Cavilon Durable Barrier was compared to glycerine cream, also known as Sorbolene. The trial was designed to evaluate the barrier cream against this comparator, indicating they are distinct products.